# A Study to Evaluate Effectiveness and Safety of Prolonged Release OROS Methylphenidate in Adults With Attention Deficit Hyperactivity Disorder

> **NCT00714688** · PHASE3 · COMPLETED · sponsor: **Janssen-Cilag International NV** · enrollment: 279 (actual)

## Conditions studied

- Attention Deficit/ Hyperactivity Disorder

## Interventions

- **DRUG:** prolonged release (PR) OROS methylphenidate 54 mg
- **DRUG:** prolonged release (PR) OROS methylphenidate 72 mg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00714688
- **Lead sponsor:** Janssen-Cilag International NV
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-02
- **Primary completion:** 2009-04
- **Final completion:** 2009-04
- **Target enrollment:** 279 (ACTUAL)
- **Last updated:** 2014-05-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00714688

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00714688, "A Study to Evaluate Effectiveness and Safety of Prolonged Release OROS Methylphenidate in Adults With Attention Deficit Hyperactivity Disorder". Retrieved via AI Analytics 2026-07-13 from https://api.ai-analytics.org/clinical/NCT00714688. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*